

Jan Nyman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3503635/publications.pdf>

Version: 2024-02-01

32
papers

1,620
citations

566801

15
h-index

476904

29
g-index

32
all docs

32
docs citations

32
times ranked

2288
citing authors

#	ARTICLE	IF	CITATIONS
1	Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 59-68.	5.1	446
2	SPACE – A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC. <i>Radiotherapy and Oncology</i> , 2016, 121, 1-8.	0.3	270
3	Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer – Mature results for medically inoperable patients. <i>Lung Cancer</i> , 2006, 51, 97-103.	0.9	239
4	The HILUS-Trial – a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1200-1210.	0.5	92
5	ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 38-47.	0.8	89
6	High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 321-331.	5.1	74
7	START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7500-7500.	0.8	40
8	Prognostic factors for head and neck cancer of unknown primary including the impact of human papilloma virus infection. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2017, 46, 45.	0.9	38
9	Effect of prophylactic percutaneous endoscopic gastrostomy tube on swallowing in advanced head and neck cancer: A randomized controlled study. <i>Head and Neck</i> , 2017, 39, 908-915.	0.9	37
10	Prognostic Factors for Local Control and Survival of Cancer of the Oral Tongue a retrospective analysis of 230 cases in Western Sweden. <i>Acta Oncologica</i> , 1993, 32, 667-673.	0.8	36
11	Can a person-centred-care intervention improve health-related quality of life in patients with head and neck cancer? A randomized, controlled study. <i>BMC Nursing</i> , 2017, 16, 9.	0.9	32
12	Systematic evaluation of lung tumor motion using four-dimensional computed tomography. <i>Acta Oncologica</i> , 2017, 56, 525-530.	0.8	30
13	Effects of Irradiation on the Biomechanics of Osseointegration: an Experimental in Vivo Study in Rats. <i>Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery</i> , 1997, 31, 281-293.	0.6	29
14	Impact on quality of life of IMRT versus 3-D conformal radiation therapy in head and neck cancer patients: A case control study. <i>Advances in Radiation Oncology</i> , 2017, 2, 346-353.	0.6	27
15	Mature results from a Swedish comparison study of conventional versus accelerated radiotherapy in head and neck squamous cell carcinoma – The ARTSCAN trial. <i>Radiotherapy and Oncology</i> , 2015, 117, 99-105.	0.3	26
16	Long-Term Aspects of Quality of Life in Head and Neck Cancer Patients Treated With Intensity Modulated Radiation Therapy: A 5-Year Longitudinal Follow-up and Comparison with a Normal Population Cohort. <i>Advances in Radiation Oncology</i> , 2020, 5, 101-110.	0.6	18
17	Results of preoperative chemoradiotherapy for patients with advanced cancer of the nasal cavity and paranasal sinuses. <i>Acta Oto-Laryngologica</i> , 2017, 137, 1292-1300.	0.3	16
18	Differences in health related quality of life in the randomised ARTSCAN study; accelerated vs. conventional radiotherapy for head and neck cancer. A five year follow up. <i>Radiotherapy and Oncology</i> , 2016, 118, 335-341.	0.3	15

#	ARTICLE	IF	CITATIONS
19	Evaluation of deformable image registration accuracy for CT images of the thorax region. <i>Physica Medica</i> , 2019, 57, 191-199.	0.4	14
20	KRAS Mutations Impact Clinical Outcome in Metastatic Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 2063.	1.7	10
21	Accelerated Hyperfractionated Radiotherapy Combined with Induction and Concomitant Chemotherapy for Inoperable Non-small-cell Lung Cancer: Impact of Total Treatment Time. <i>Acta OncolÅ³gica</i> , 1998, 37, 539-545.	0.8	7
22	The unannounced patient in the corridor: trust, friction and person-centered care. <i>International Journal of Health Planning and Management</i> , 2017, 32, e1-e16.	0.7	6
23	Double strand break induction and kinetics indicate preserved hypersensitivity in keratinocytes to subtherapeutic doses for 7weeks of radiotherapy. <i>Radiotherapy and Oncology</i> , 2017, 122, 163-169.	0.3	6
24	Analysis of early respiratory-related mortality after radiation therapy of non-small-cell lung cancer: feasibility of automatic data extraction for doseâ€™response studies. <i>Acta OncolÅ³gica</i> , 2020, 59, 628-635.	0.8	5
25	The effect of age on health-related quality of life for head and neck cancer patients up to 1 year after curative treatment. <i>Journal of Geriatric Oncology</i> , 2022, 13, 60-66.	0.5	5
26	Randomized phase II trial comparing the efficacy of standard-dose with high-dose twice-daily thoracic radiotherapy (TRT) in limited disease small-cell lung cancer (LD SCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9007-9007.	0.8	5
27	Harmonization of proton treatment planning for head and neck cancer using pencil beam scanning: first report of the IPACS collaboration group. <i>Acta OncolÅ³gica</i> , 2019, 58, 1720-1730.	0.8	4
28	Effect of Increased Radiotoxicity on Survival of Patients with Non-small Cell Lung Cancer Treated with Curatively Intended Radiotherapy. <i>Anticancer Research</i> , 2015, 35, 5491-7.	0.5	3
29	Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer. <i>Lung Cancer</i> , 2022, 166, 49-57.	0.9	1
30	Reply to Alongi et al.. <i>Radiotherapy and Oncology</i> , 2017, 122, 320.	0.3	0
31	Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer â€™ Authors' reply. <i>Lancet Oncology</i> , The, 2021, 22, e222.	5.1	0
32	The ACCROBAT I study: Three-year follow-up of a prospective phase II study with neoadjuvant TPF before bioradiotherapy for stage III-IV unresectable squamous cell head and neck cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e17004-e17004.	0.8	0